Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totaling 9,143 shares, a decline of 44.2% from the May 31st total of 16,388 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 19,697 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Xenetic Biosciences Stock Performance

NASDAQ:XBIO opened at $2.83 on Friday. The stock has a market capitalization of $6.48 million, a PE ratio of -2.36 and a beta of 2.19. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93. The company has a fifty day moving average of $3.05 and a two-hundred day moving average of $2.71.

Xenetic Biosciences (NASDAQ:XBIO) last announced its earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. The company had revenue of $0.81 million during the quarter. Xenetic Biosciences had a negative net margin of 70.03% and a negative return on equity of 39.28%.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC acquired a new position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned approximately 0.60% of Xenetic Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.